Upgrade to SI Premium - Free Trial

Connect Biopharma (CNTB)

2.17 -0.13 (5.65%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (2/12/26 *Est.)

Latest Headlines

Form 4 Connect Biopharma Holdin For: May 29 Filed by: Huang James June 2, 2026 4:31 PM - SEC Filing Form EFFECT Connect Biopharma Holdin June 2, 2026 6:09 AM - SEC Filing Canaccord Starts Connect Biopharma Holdings Ltd (CNTB) at Buy May 26, 2026 5:06 AM - StreetInsider Cantor Fitzgerald Starts Connect Biopharma Holdings Ltd (CNTB) at Overweight May 21, 2026 6:08 AM - StreetInsider Form SCHEDULE 13G/A Connect Biopharma Holdin Filed by: Wei Zheng May 15, 2026 1:48 PM - SEC Filing Form F-3 Connect Biopharma Holdin May 15, 2026 8:32 AM - SEC Filing Connect Biopharma to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference May 12, 2026 4:05 PM - StreetInsider Form 10-Q Connect Biopharma Holdin For: Mar 31 May 12, 2026 9:04 AM - SEC Filing Form 8-K Connect Biopharma Holdin For: May 12 May 12, 2026 9:02 AM - SEC Filing Connect Biopharma Reports First Quarter 2026 Financial Results and Provides Business Update May 12, 2026 9:00 AM - StreetInsider Form 8-K Connect Biopharma Holdin For: Apr 23 April 23, 2026 9:05 AM - SEC Filing Connect Biopharma continues Phase 2 asthma, COPD trials after interim review April 23, 2026 9:01 AM - StreetInsider Connect Biopharma Announces Enrollment in Phase 2 Seabreeze STAT Studies Will Continue as Planned Following Pre-Specified Interim Analysis April 23, 2026 9:01 AM - Globe NewsWire Form SCHEDULE 13G Connect Biopharma Holdin Filed by: BioFortune Inc April 14, 2026 11:14 AM - SEC Filing Ickey Woods Kicks Off "Score 6 for 24" Fundraising Campaign to Expand Asthma Testing for Children Nationwide April 13, 2026 7:00 AM - PR NewsWire RedChip's April 16 Virtual Investor Conference to Feature Companies Advancing Clinical Pipelines and Scalable Healthcare Platforms April 7, 2026 11:00 AM - StreetInsider Form 4 Connect Biopharma Holdin For: Mar 31 Filed by: Xanthopoulos Kleanthis Gabriel April 2, 2026 4:28 PM - SEC Filing Form 4 Connect Biopharma Holdin For: Mar 31 Filed by: LIU JEAN I April 2, 2026 4:25 PM - SEC Filing Form 4 Connect Biopharma Holdin For: Mar 31 Filed by: Huang James April 1, 2026 4:31 PM - SEC Filing Form SCHEDULE 13D/A Connect Biopharma Holdin Filed by: Panacea Innovation Ltd April 1, 2026 4:30 PM - SEC Filing Form 10-K Connect Biopharma Holdin For: Dec 31 March 31, 2026 4:11 PM - SEC Filing Form 8-K Connect Biopharma Holdin For: Mar 31 March 31, 2026 4:09 PM - SEC Filing Connect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update March 31, 2026 4:05 PM - StreetInsider BTIG Reiterates Buy Rating on Connect Biopharma Holdings Ltd (CNTB) March 31, 2026 5:19 AM - StreetInsider Signadori Bio appoints Dr. Selwyn Ho, MB BS as Chief Executive Officer to lead company into next stage of growth March 31, 2026 2:00 AM - BizWire Form 8-K Connect Biopharma Holdin For: Mar 29 March 30, 2026 7:06 AM - SEC Filing Connect Biopharma raises $20.2 million in private placement March 30, 2026 7:02 AM - StreetInsider Connect Biopharma Announces $20.2 Million Private Placement Financing March 30, 2026 7:02 AM - StreetInsider Connect Biopharma reports positive Phase 3 atopic dermatitis results March 30, 2026 7:01 AM - StreetInsider Rademikibart Demonstrates Best-in-Class Potential in Phase 3 Atopic Dermatitis Study March 30, 2026 7:01 AM - StreetInsider Connect Biopharma reports positive phase 1 data for asthma, COPD drug March 30, 2026 7:00 AM - StreetInsider Connect Biopharma Announces Positive Topline Data from its Phase 1 Study of Intravenous (IV) Rademikibart in Patients with Asthma or COPD March 30, 2026 7:00 AM - StreetInsider Form 3 Connect Biopharma Holdin For: Mar 18 Filed by: Huang James March 18, 2026 4:33 PM - SEC Filing Epidermolysis Bullosa Market Set for Significant Upswing During the Forecast Period (2025-2034) Amid Rising Therapeutic Advancements | DelveInsight March 17, 2026 10:01 AM - PR NewsWire Form 3 Connect Biopharma Holdin For: Mar 16 Filed by: Szekeres David Leslie March 16, 2026 4:48 PM - SEC Filing Form 3 Connect Biopharma Holdin For: Mar 16 Filed by: Quart Barry D March 16, 2026 4:47 PM - SEC Filing Form 3 Connect Biopharma Holdin For: Mar 16 Filed by: Peraza Lisa March 16, 2026 4:47 PM - SEC Filing Form 3 Connect Biopharma Holdin For: Mar 16 Filed by: Xanthopoulos Kleanthis Gabriel March 16, 2026 4:45 PM - SEC Filing Form 3 Connect Biopharma Holdin For: Mar 16 Filed by: WILSON KAREN J March 16, 2026 4:43 PM - SEC Filing Form 3 Connect Biopharma Holdin For: Mar 16 Filed by: Schoeneck James A March 16, 2026 4:43 PM - SEC Filing Form 3 Connect Biopharma Holdin For: Mar 16 Filed by: LIU JEAN I March 16, 2026 4:40 PM - SEC Filing Connect Biopharma Phase 3 atopic dermatitis study to be presented at AAD March 10, 2026 9:00 AM - StreetInsider Results from Phase 3 Study of Rademikibart in Moderate-to-Severe Atopic Dermatitis to be Presented in the Late-Breaking Research Session at the 2026 American Academy of Dermatology (AAD) Annual Meetin March 10, 2026 9:00 AM - StreetInsider Full Article List